Arrowhead Historical Income Statement
ARWR Stock | USD 22.08 2.64 10.68% |
Historical analysis of Arrowhead Pharmaceuticals income statement accounts such as Interest Expense of 20 M, Selling General Administrative of 79.1 M or Selling And Marketing Expenses of 8.2 B can show how well Arrowhead Pharmaceuticals performed in making a profits. Evaluating Arrowhead Pharmaceuticals income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Arrowhead Pharmaceuticals's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Arrowhead Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Arrowhead Pharmaceuticals is a good buy for the upcoming year.
Arrowhead |
About Arrowhead Income Statement Analysis
Arrowhead Pharmaceuticals Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Arrowhead Pharmaceuticals shareholders. The income statement also shows Arrowhead investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Arrowhead Pharmaceuticals Income Statement Chart
Arrowhead Pharmaceuticals Income Statement is one of the three primary financial statements used for reporting Arrowhead's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Arrowhead Pharmaceuticals revenue and expense. Arrowhead Pharmaceuticals Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, Arrowhead Pharmaceuticals' Income Tax Expense is relatively stable compared to the past year. As of 05/12/2024, Research Development is likely to grow to about 426.5 M, while Selling General Administrative is likely to drop slightly above 79.1 M. Add Fundamental
Total Revenue
Total revenue comprises all receipts Arrowhead Pharmaceuticals generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.Gross Profit
Gross profit is a required income statement account that reflects total revenue of Arrowhead Pharmaceuticals minus its cost of goods sold. It is profit before Arrowhead Pharmaceuticals operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.Most accounts from Arrowhead Pharmaceuticals' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Arrowhead Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Arrowhead Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in housing. To learn how to invest in Arrowhead Stock, please use our How to Invest in Arrowhead Pharmaceuticals guide.At this time, Arrowhead Pharmaceuticals' Income Tax Expense is relatively stable compared to the past year. As of 05/12/2024, Research Development is likely to grow to about 426.5 M, while Selling General Administrative is likely to drop slightly above 79.1 M.
2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 243.2M | 228.2M | 262.5M | 275.6M | Total Revenue | 243.2M | 240.7M | 276.8M | 290.7M |
Arrowhead Pharmaceuticals income statement Correlations
Click cells to compare fundamentals
Arrowhead Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Arrowhead Pharmaceuticals income statement Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Depreciation And Amortization | 5.9M | 8.3M | 10.4M | 12.5M | 14.4M | 15.1M | |
Interest Expense | 9.2B | 6.1M | 5.0M | 18.3M | 21.1M | 20.0M | |
Selling General Administrative | 52.3M | 81.0M | 124.4M | 92.5M | 83.3M | 79.1M | |
Total Revenue | 88.0M | 138.3M | 243.2M | 240.7M | 276.8M | 290.7M | |
Gross Profit | 88.0M | 138.3M | 243.2M | 228.2M | 262.5M | 275.6M | |
Other Operating Expenses | 181.2M | 287.3M | 421.7M | 445.7M | 512.6M | 538.2M | |
Operating Income | (93.2M) | (149.0M) | (178.5M) | (205.0M) | (184.5M) | (175.3M) | |
Ebit | (93.2M) | (149.0M) | (178.5M) | (200.7M) | (180.6M) | (171.6M) | |
Ebitda | (87.2M) | (140.8M) | (168.1M) | (188.2M) | (169.3M) | (160.9M) | |
Total Operating Expenses | 181.2M | 287.3M | 421.7M | 445.7M | 512.6M | 538.2M | |
Income Before Tax | (84.6M) | (140.8M) | (172.7M) | (206.5M) | (185.8M) | (176.5M) | |
Total Other Income Expense Net | 8.6M | 8.2M | 5.8M | 1.5M | 1.8M | 888.4K | |
Net Income | (84.6M) | (140.8M) | (176.5M) | (205.3M) | (184.7M) | (175.5M) | |
Research Development | 128.9M | 206.3M | 297.3M | 353.2M | 406.2M | 426.5M | |
Net Income From Continuing Ops | (84.6M) | (140.8M) | (172.7M) | (209.3M) | (188.3M) | (178.9M) | |
Net Income Applicable To Common Shares | (84.6M) | (140.8M) | (176.1M) | (205.3M) | (184.7M) | (175.5M) | |
Net Interest Income | 9.2M | 6.1M | 5.0M | (3.0M) | (3.5M) | (3.3M) | |
Reconciled Depreciation | 5.9M | 8.3M | 10.4M | 12.5M | 14.4M | 8.0M |
Pair Trading with Arrowhead Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Arrowhead Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Arrowhead Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving together with Arrowhead Stock
0.87 | EGRX | Eagle Pharmaceuticals | PairCorr |
Moving against Arrowhead Stock
0.75 | VRCA | Verrica Pharmaceuticals Earnings Call Tomorrow | PairCorr |
0.67 | YCBD | cbdMD Inc Earnings Call Tomorrow | PairCorr |
0.53 | ELYM | Eliem Therapeutics Earnings Call Tomorrow | PairCorr |
0.51 | JANX | Janux Therapeutics Financial Report 14th of May 2024 | PairCorr |
The ability to find closely correlated positions to Arrowhead Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Arrowhead Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Arrowhead Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Arrowhead Pharmaceuticals to buy it.
The correlation of Arrowhead Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Arrowhead Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Arrowhead Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Arrowhead Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Arrowhead Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in housing. To learn how to invest in Arrowhead Stock, please use our How to Invest in Arrowhead Pharmaceuticals guide.You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Complementary Tools for Arrowhead Stock analysis
When running Arrowhead Pharmaceuticals' price analysis, check to measure Arrowhead Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arrowhead Pharmaceuticals is operating at the current time. Most of Arrowhead Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Arrowhead Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arrowhead Pharmaceuticals' price. Additionally, you may evaluate how the addition of Arrowhead Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance |
Is Arrowhead Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Arrowhead Pharmaceuticals. If investors know Arrowhead will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Arrowhead Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.098 | Earnings Share (2.77) | Revenue Per Share 0.319 | Quarterly Revenue Growth (0.94) | Return On Assets (0.32) |
The market value of Arrowhead Pharmaceuticals is measured differently than its book value, which is the value of Arrowhead that is recorded on the company's balance sheet. Investors also form their own opinion of Arrowhead Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Arrowhead Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Arrowhead Pharmaceuticals' market value can be influenced by many factors that don't directly affect Arrowhead Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Arrowhead Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Arrowhead Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Arrowhead Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.